Exenatide, a GLP-1 receptor agonist developed to treat type 2 diabetes, failed to demonstrate a significant benefit in slowing Parkinson's disease progression in a major clinical trial published in The Lancet on February 4, 2025. The phase 3 Exenatide-PD3 study followed 194 patients for 96 weeks and found no statistically significant improvement in motor symptoms compared with a placebo. However, the study's reliability came under additional scrutiny in June 2026 when The Lancet issued an Expression of Concern over problems involving clinical trial oversight at one participating hospital.
What Did the Exenatide Parkinson's Trial Find?
The Exenatide-PD3 trial was designed to determine whether exenatide could slow the progression of Parkinson's disease, a neurological disorder that gradually damages dopamine-producing neurons and affects movement.
Researchers from University College London and collaborating institutions conducted the randomized, double-blind, placebo-controlled study across six UK hospitals.
Participants received either weekly injections of extended-release exenatide or an inactive placebo for 96 weeks. Researchers evaluated whether the medication could reduce the deterioration of movement-related symptoms.
The primary findings showed no statistically significant advantage for exenatide. Motor disability worsened in both treatment groups, with no reliable evidence that the medication slowed disease progression.
Exenatide-PD3 Clinical Trial Results
The study enrolled 194 participants between January 2020 and April 2022. Patients were randomly assigned to two equally sized groups:
- Exenatide: 97 participants received a 2 mg extended-release injection once weekly.
- Placebo: 97 participants received an inactive injection using an identical treatment schedule.
Motor symptoms were measured using Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Higher scores indicate more severe movement impairment.
The primary assessment was conducted after participants temporarily withheld their usual dopaminergic medication, allowing researchers to evaluate motor performance without its immediate effects.
Motor Symptoms Worsened in Both Groups
After 96 weeks, the mean motor score increased by 5.7 points in the exenatide group, compared with 4.5 points in the placebo group.
The adjusted treatment effect was 0.92 points, with a 95% confidence interval of -1.56 to 3.39 and a p-value of 0.47.
Because the difference was not statistically significant, the trial did not demonstrate that exenatide improved motor outcomes or reduced disease progression.
The researchers also found no significant benefit in several secondary outcomes, including motor assessments while participants were taking Parkinson's medication, non-motor symptoms, quality of life and changes in medication requirements.
Safety and Adverse Events
At least one serious adverse event was reported in nine participants receiving exenatide, approximately 9% of the group, compared with 11 participants, or approximately 11%, receiving placebo.
The investigators described exenatide as generally safe and well tolerated within the trial. However, the absence of demonstrated clinical benefit did not support its use as a treatment intended to modify Parkinson's disease progression.
Why Was Exenatide Considered a Potential Parkinson's Treatment?
Exenatide belongs to a class of medications called glucagon-like peptide-1 receptor agonists, or GLP-1 receptor agonists. These drugs were initially developed to improve blood glucose regulation in people with type 2 diabetes.
Researchers became interested in their neurological effects after laboratory and animal experiments suggested that GLP-1 signaling could influence inflammation, cellular energy regulation and mechanisms associated with nerve-cell survival.
These biological processes are relevant to Parkinson's disease, which involves progressive degeneration of dopamine-producing neurons.
Earlier human research also provided encouraging results. A smaller randomized trial published in The Lancet in 2017 involved 62 patients and reported improvements in off-medication motor scores among participants receiving exenatide.
However, the researchers could not determine whether those improvements reflected protection against neurodegeneration or longer-lasting symptomatic effects.
The larger Exenatide-PD3 trial was intended to establish whether the earlier findings could be reproduced over a longer treatment period.
The Lancet Issued an Expression of Concern in June 2026
On June 22, 2026, The Lancet published an Expression of Concern regarding the Exenatide-PD3 study. The notice appeared in the journal's June 27 issue.
The journal reported that it had been informed of findings from a regulatory inspection involving King's College Hospital NHS Foundation Trust, one of the study's participating sites.
The inspection identified wider departmental concerns involving clinical trial conduct, oversight and governance. Some findings were classified as critical or major.
The Lancet stated that further investigation was necessary to determine whether the issues could affect the study's data or conclusions.
An Expression of Concern is not the same as a retraction. It indicates that questions about a publication remain unresolved and that readers should interpret the research with appropriate caution.
As of November 2026, the original trial's negative findings should therefore be considered alongside this formal editorial warning.
What Do Other GLP-1 Trials Show About Parkinson's Disease?
The disappointing exenatide results do not necessarily mean that every GLP-1 medication will produce the same outcome.
Several drugs in this class have been studied for potential neurological benefits, including lixisenatide, liraglutide and the experimental GLP-1-related compound NLY01.
Lixisenatide Showed Encouraging Results in a Smaller Trial
A phase 2 trial published in The New England Journal of Medicine in April 2024 examined lixisenatide in 156 people with early Parkinson's disease.
After 12 months, motor disability scores had remained almost unchanged in the lixisenatide group but worsened by approximately three points in the placebo group.
The between-group difference was statistically significant, suggesting a potential benefit that warranted further investigation.
However, lixisenatide caused gastrointestinal side effects, including nausea in 46% of treated participants and vomiting in 13%.
The study was relatively small, and longer trials are required to determine whether the medication genuinely slows the underlying disease rather than temporarily affecting symptoms.
Meta-Analyses Published in 2026 Report Mixed Findings
A systematic review published in January 2026 combined four randomized clinical trials involving 667 patients. It found no significant overall improvement in motor or non-motor symptoms among those receiving GLP-1 receptor agonists compared with placebo.
Another review published in May 2026 similarly found no consistent clinical benefit across most Parkinson's outcomes, although it identified a small statistically significant difference in one quality-of-life measure.
Other analyses reached more encouraging conclusions. An April 2026 network meta-analysis involving 708 participants reported possible motor improvements associated with certain drug regimens, while a July 2026 meta-analysis of 850 patients found a modest overall motor benefit.
These differences reflect variation in the included trials, medications, doses, outcome measurements and statistical methods. Some positive findings were exploratory, and the analyses do not establish that GLP-1 drugs prevent neurological deterioration.
Overall, research published through 2026 has not demonstrated consistent disease-modifying benefits across this medication class.
Does the Exenatide Failure Mean Ozempic Cannot Help Parkinson's?
No. The Exenatide-PD3 results apply specifically to the tested formulation, dose, population and treatment duration. They do not establish the effectiveness or ineffectiveness of every other GLP-1 receptor agonist.
Ozempic contains semaglutide, a different medication within the same broad class. Although GLP-1 drugs share certain biological mechanisms, they differ in molecular structure, pharmacological activity and other properties that could influence neurological effects.
However, the potential benefits of one GLP-1 medication cannot be assumed from studies involving another.
There is currently insufficient clinical evidence to recommend semaglutide, exenatide or other GLP-1 receptor agonists specifically to slow Parkinson's disease outside an appropriate research setting.
What the Results Mean for Parkinson's Patients
The Exenatide-PD3 findings represent a setback in the search for treatments capable of slowing Parkinson's disease, but they do not change established approaches to symptom management.
Current treatment commonly involves levodopa and other medications that help address dopamine-related movement difficulties. Physical activity, rehabilitation and individualized supportive care also play important roles.
For selected patients, advanced interventions such as deep brain stimulation may improve symptoms that are difficult to manage with medication alone.
None of these approaches should be confused with a proven treatment that halts the underlying neurodegenerative process.
People who already take exenatide or another GLP-1 drug for an approved medical condition should not discontinue their medication based solely on the Parkinson's research findings. Treatment decisions should be discussed with their healthcare professional.
What Researchers Need to Investigate Next
Future studies will need to determine whether specific GLP-1 medications can reach relevant neurological targets and produce sustained clinical benefits.
Important questions include whether treatment earlier in Parkinson's disease offers advantages, whether certain patient subgroups respond differently and which biological measurements can reliably demonstrate slower neurodegeneration.
Researchers must also account for the gastrointestinal side effects and weight loss associated with GLP-1 receptor agonists, particularly in patients who may already experience nutritional or gastrointestinal difficulties.
Well-controlled clinical trials with adequate follow-up periods, transparent reporting and rigorous oversight will be essential for establishing the potential role of this drug class in Parkinson's treatment.
Conclusion
The phase 3 Exenatide-PD3 trial reported no statistically significant improvement in Parkinson's motor symptoms or evidence of slower disease progression after 96 weeks of weekly exenatide treatment.
The Lancet's June 2026 Expression of Concern introduced additional uncertainty about the study's reliability because of unresolved trial-governance concerns at one participating hospital.
Meanwhile, research involving other GLP-1 receptor agonists has produced mixed results, with some smaller trials suggesting potential benefits that have not been consistently confirmed.
As of November 2026, GLP-1 medications remain investigational as disease-modifying therapies for Parkinson's disease. Larger, carefully conducted trials are needed before any drug in this class can be considered an established treatment for slowing the condition.
- Log in to post comments